Ponatinib vs AlloSCT in CML or Ph+ ALL With T315I Mutation

December 5-8, 2015; Orlando, Florida
Retrospective observational data indicated that ponatinib achieved significantly longer OS in T315I+ CP-CML vs alloSCT.
Format: Microsoft PowerPoint (.ppt)
File Size: 519 KB
Released: December 12, 2015


Educational grant provided by:
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics
Takeda Oncology

Related Content

Spotlight on approved and investigational targeted agents for patients with AML mutations FLT3, IDH1/2, or BCL2, and other targets in AML.

Farhad Ravandi, MD Released: October 15, 2018

Online interactive tool provides expert treatment recommendations for individual CLL case scenarios

Farrukh T. Awan, MD Released: October 10, 2018

Downloadable PDF clinical resource reviewing clinical data on first-line treatment of follicular lymphoma.

Released: October 4, 2018

Review case-based expert treatment recommendations with new drugs in patients with transplantation-eligible and transplantation-ineligible multiple myeloma.

Shaji Kumar, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: October 3, 2018 Expiration: October 2, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?